- Home
- SWTX vs NGD Comparison
SWTX vs NGD Comparison
Compare SWTX & NGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWTX
- NGD
- Stock Information
- Founded
- SWTX 2017
- NGD N/A
- Country
- SWTX United States
- NGD Canada
- Employees
- SWTX N/A
- NGD N/A
- Industry
- SWTX Biotechnology: Pharmaceutical Preparations
- NGD
- Sector
- SWTX Health Care
- NGD
- Exchange
- SWTX Nasdaq
- NGD Nasdaq
- Market Cap
- SWTX 3.5B
- NGD 3.1B
- IPO Year
- SWTX 2019
- NGD 2004
- Fundamental
- Price
- SWTX $46.26
- NGD $4.18
- Analyst Decision
- SWTX Buy
- NGD Buy
- Analyst Count
- SWTX 7
- NGD 3
- Target Price
- SWTX $56.86
- NGD $4.33
- AVG Volume (30 Days)
- SWTX 8.7M
- NGD 27.2M
- Earning Date
- SWTX 05-20-2025
- NGD 04-29-2025
- Dividend Yield
- SWTX N/A
- NGD N/A
- EPS Growth
- SWTX N/A
- NGD N/A
- EPS
- SWTX N/A
- NGD 0.17
- Revenue
- SWTX $191,589,000.00
- NGD $941,500,000.00
- Revenue This Year
- SWTX $86.36
- NGD $32.72
- Revenue Next Year
- SWTX $69.02
- NGD $42.38
- P/E Ratio
- SWTX N/A
- NGD $25.10
- Revenue Growth
- SWTX 3417.33
- NGD 21.17
- 52 Week Low
- SWTX $28.21
- NGD $1.74
- 52 Week High
- SWTX $62.00
- NGD $4.21
- Technical
- Relative Strength Index (RSI)
- SWTX 58.93
- NGD 65.60
- Support Level
- SWTX $46.10
- NGD $3.28
- Resistance Level
- SWTX $46.27
- NGD $4.21
- Average True Range (ATR)
- SWTX 0.90
- NGD 0.20
- MACD
- SWTX 0.58
- NGD 0.05
- Stochastic Oscillator
- SWTX 99.46
- NGD 96.84
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets which are also its operating segments: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.